Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 References

Delgocitinib

●日本語 ●Polski Edit links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia

Delgocitinib
Clinical data

Trade names	Corectim
Other names	JTE-052; JTE-052A
ATC code	D11AH11 (WHO)
Legal status
Legal status	Rx-only in Japan
Identifiers
IUPAC name 3-[(3S,4R)-3-Methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
CAS Number	1263774-59-9
PubChem CID	50914062
DrugBank	DB16133
ChemSpider	59718502
UNII	9L0Q8KK220
KEGG	D11046
CompTox Dashboard (EPA)	DTXSID401336933
Chemical and physical data
Formula	C₁₆H₁₈N₆O
Molar mass	310.361 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
InChI InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1 Key:LOWWYYZBZNSPDT-ZBEGNZNMSA-N

Delgocitinib (brand name Corectim) is a pharmaceutical drug for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions.^[1] Delgocitinib was developedbyJapan Tobacco and approved in Japan for the treatment of atopic dermatitis.^[1] In the United States, delgocitinib is in Phase III clinical trials and the Food and Drug Administration has granted delgocitinib Fast Track designation for topical treatment of adults with moderate to severe chronic hand eczema.^[2]

Delgocitinib works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases.^[3]

References[edit]

^ ^a ^b Dhillon S (April 2020). "Delgocitinib: First Approval". Drugs. 80 (6): 609–615. doi:10.1007/s40265-020-01291-2. PMID 32166597. S2CID 212681247.

^ Park B (August 5, 2020). "Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema". empr.com.

^ Szalus K, Trzeciak M, Nowicki RJ (November 2020). "JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results". Microorganisms. 8 (11): 1743. doi:10.3390/microorganisms8111743. PMC 7694787. PMID 33172122.

This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Delgocitinib&oldid=1190505428" Categories: ●Dermatologic drugs ●Non-receptor tyrosine kinase inhibitors ●Pyrrolopyrimidines ●Spiro compounds ●Nitriles ●Amides ●Antineoplastic and immunomodulating drug stubs Hidden categories: ●Articles with short description ●Short description matches Wikidata ●Drugs with non-standard legal status ●Articles without EBI source ●Articles containing unverified chemical infoboxes ●All stub articles ●This page was last edited on 18 December 2023, at 07:37 (UTC). ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization. ●Privacy policy ●About Wikipedia ●Disclaimers ●Contact Wikipedia ●Code of Conduct ●Developers ●Statistics ●Cookie statement ●Mobile view